RT Journal Article
SR Electronic
T1 Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2814
VO 42
IS Suppl 57
A1 Svitlana Cherenko
A1 Nataliia Lytvynenko
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P2814.abstract
AB Background. The treatment of patients with multidrug-resistant tuberculosis (MDR-TB) is a major issue due to high level of morbidity and mortality. The way to improve the outcomes in patients with MDR-TB is using some anti-tuberculosis drugs (ATD) in intravenous route. The objectives of this study were to evaluate the efficacy of intravenous versus oral administration of some ATD in patients with MDR-TB and to compare the main cost of these two regimens.Methods. In the randomized controlled open-label clinical trial 60 individuals with MDR-TB received chemotherapy regimens included not less than 5 effectiveness anti-tuberculosis drugs (to which sensitivity of MBT is kept). These regimens differed only in that the patients of the main group received ethambutol (25 mg/kg), levofloxacin (15 mg/kg) and PAS (150 mg/kg) intravenously; the patients of the control received the same drugs in the same doses via oral route. Results. In patients of main group sputum conversion achieved in 83.3% vs. 60.0% of control (p<0,05). The time to sputum conversion in the main group was significantly shorter vs. control: 3,7 months vs 4,8 months, respectively (p <0,05), which allowed to save $ 4543.9 USD per patient. Conclusions. Administration of intravenous ATD in regimens of chemotherapy allows to improve the outcomes in patients with MDR-TB and save total cost of treatment.